Literature DB >> 25581405

Ponatinib given for advanced leukemia relapse after allo-SCT.

K Hirschbuehl1, A Rank1, T Pfeiffer1, H R Slawik2, G Schlimok1, H J Kolb3, Ch Schmid1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25581405     DOI： 10.1038/bmt.2014.301

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  8 in total

1.  Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse After Hematopoietic Stem Cell Transplantation: part III. Prevention and treatment of relapse after allogeneic transplantation.

Authors:  Marcos de Lima; David L Porter; Minoo Battiwalla; Michael R Bishop; Sergio A Giralt; Nancy M Hardy; Nicolaus Kröger; Alan S Wayne; Christoph Schmid
Journal:  Biol Blood Marrow Transplant       Date:  2013-09-07       Impact factor: 5.742

2.  Ponatinib in Philadelphia chromosome-positive leukemias.

Authors:  Alfonso Quintas-Cardama
Journal:  N Engl J Med       Date:  2014-02-06       Impact factor: 91.245

Review 3.  Standardized definitions of molecular response in chronic myeloid leukemia.

Authors:  N C P Cross; H E White; M C Müller; G Saglio; A Hochhaus
Journal:  Leukemia       Date:  2012-04-16       Impact factor: 11.528

4.  Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study.

Authors:  Georg Hess; Donald Bunjes; Wolfgang Siegert; Rainer Schwerdtfeger; Georg Ledderose; Barbara Wassmann; Guido Kobbe; Martin Bornhäuser; Andreas Hochhaus; Andrew J Ullmann; Thomas Kindler; Ulrike Haus; Harald Gschaidmeier; Christoph Huber; Thomas Fischer
Journal:  J Clin Oncol       Date:  2005-10-20       Impact factor: 44.544

Review 5.  Current status and perspectives of tyrosine kinase inhibitor treatment in the posttransplant period in patients with chronic myelogenous leukemia (CML).

Authors:  Evgeny Klyuchnikov; Nicolaus Kröger; Tim H Brummendorf; Bettina Wiedemann; Axel Rolf Zander; Ulrike Bacher
Journal:  Biol Blood Marrow Transplant       Date:  2009-09-08       Impact factor: 5.742

6.  A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias.

Authors:  J E Cortes; D-W Kim; J Pinilla-Ibarz; P le Coutre; R Paquette; C Chuah; F E Nicolini; J F Apperley; H J Khoury; M Talpaz; J DiPersio; D J DeAngelo; E Abruzzese; D Rea; M Baccarani; M C Müller; C Gambacorti-Passerini; S Wong; S Lustgarten; V M Rivera; T Clackson; C D Turner; F G Haluska; F Guilhot; M W Deininger; A Hochhaus; T Hughes; J M Goldman; N P Shah; H Kantarjian
Journal:  N Engl J Med       Date:  2013-11-01       Impact factor: 91.245

7.  Ponatinib in refractory Philadelphia chromosome-positive leukemias.

Authors:  Jorge E Cortes; Hagop Kantarjian; Neil P Shah; Dale Bixby; Michael J Mauro; Ian Flinn; Thomas O'Hare; Simin Hu; Narayana I Narasimhan; Victor M Rivera; Tim Clackson; Christopher D Turner; Frank G Haluska; Brian J Druker; Michael W N Deininger; Moshe Talpaz
Journal:  N Engl J Med       Date:  2012-11-29       Impact factor: 91.245

8.  Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease.

Authors:  Daniel J DeAngelo; Ephraim P Hochberg; Edwin P Alyea; Janina Longtine; Stephanie Lee; Ilene Galinsky; Ben Parekkedon; Jerome Ritz; Joseph H Antin; Richard M Stone; Robert J Soiffer
Journal:  Clin Cancer Res       Date:  2004-08-01       Impact factor: 12.531
  8 in total
  4 in total

1.  BCR-ABL Mutation-Guided Therapy for CML Blast Crisis: A Case Report.

Authors:  Benjamin N Ostendorf; Hendrik Nogai; Claudia D Baldus; Thomas Burmeister; Renate Arnold
Journal:  Biomark Insights       Date:  2015-08-30

2.  Large Vessel Vasculitis as a Possible Mechanism of Vascular Side Effects of Ponatinib: A Case Report.

Authors:  Klaus Hirschbuehl; Andreas Rank; Tim Pfeiffer; Tina Schaller; Thomas Haeckel; Joerg Roeling; Dmytro Vlasenko; Martin Trepel; Christoph Schmid
Journal:  J Hematol (Brossard)       Date:  2019-06-30

Review 3.  Efficacy of Dasatinib in a CML Patient in Blast Crisis with F317L Mutation: A Case Report and Literature Review.

Authors:  E V Morozova; Y Y Vlasova; M V Pryanishnikova; K V Lepik; B V Afanasyev
Journal:  Biomark Insights       Date:  2015-12-08

4.  Chronic Myeloid Leukemia Relapsing 25 Years after Allogenic Stem Cell Transplantation.

Authors:  Håkon Reikvam; Jørn Skavland; Stein-Erik Gullaksen; Randi Hovland; Tobias Gedde-Dahl; Øystein Bruserud; Bjørn Tore Gjertsen
Journal:  Case Rep Hematol       Date:  2018-09-23
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.